Smartlab Europe

Serum Institute of India COVID-19 Vaccine advances to trial for phase-III on 1500 Indian patients

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Oral Microbiome Research and Its Implications for Future Therapeutics

Over the past decade, microbiome science has reshaped how...

Sanofi Secures Global Rights to Rovadicitinib in $1.53B Deal

Sanofi has committed up to $1.53 billion to obtain...

UK Invests £47.8M to Expand NHS Clinical Trial Capacity

The UK government has announced nearly £50 million in...
- Advertisement -

Serum institute has completed phase II-B3 trails and will commence phase-III trail after clearances. The third phase trail will be tested on 1500 patients at 14 locations. Balram Bhargava, Director general of the Indian Council of Medical Research, said, “The testing will not be random and will only be tested on those who show COVID-19 symptoms.”

The Oxford vaccine is in the most advanced stages of being developed, and is predicted release in the next two months.

Zycov D and Bharat have cleared phase 1 trails on humans. Zydus Cadila says it may be able to launch the vaccine by next year. Researchers continue efforts on releasing COVID vaccines.

Latest stories

Related stories

Oral Microbiome Research and Its Implications for Future Therapeutics

Over the past decade, microbiome science has reshaped how...

Sanofi Secures Global Rights to Rovadicitinib in $1.53B Deal

Sanofi has committed up to $1.53 billion to obtain...

UK Invests £47.8M to Expand NHS Clinical Trial Capacity

The UK government has announced nearly £50 million in...

CMS Extends GENEROUS MFN Drug Pricing Deadline to April

The Centers for Medicare & Medicaid Services (CMS) in...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »